These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. A review on prevention of glycation of proteins: Potential therapeutic substances to mitigate the severity of diabetes complications. Sarmah S; Roy AS Int J Biol Macromol; 2022 Jan; 195():565-588. PubMed ID: 34920073 [TBL] [Abstract][Full Text] [Related]
25. Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress. Kurz A; Rabbani N; Walter M; Bonin M; Thornalley P; Auburger G; Gispert S Cell Mol Life Sci; 2011 Feb; 68(4):721-33. PubMed ID: 20711648 [TBL] [Abstract][Full Text] [Related]
26. Ribosylation rapidly induces alpha-synuclein to form highly cytotoxic molten globules of advanced glycation end products. Chen L; Wei Y; Wang X; He R PLoS One; 2010 Feb; 5(2):e9052. PubMed ID: 20140223 [TBL] [Abstract][Full Text] [Related]
30. Protein Repair from Glycation by Glyoxals by the DJ-1 Family Maillard Deglycases. Mihoub M; Abdallah J; Richarme G Adv Exp Med Biol; 2017; 1037():133-147. PubMed ID: 29147907 [TBL] [Abstract][Full Text] [Related]
31. Bimolecular interaction of argpyrimidine (a Maillard reaction product) in in vitro non-enzymatic protein glycation model and its potential role as an antiglycating agent. Bhattacherjee A; Dhara K; Chakraborti AS Int J Biol Macromol; 2017 Sep; 102():1274-1285. PubMed ID: 28487198 [TBL] [Abstract][Full Text] [Related]
33. Glycation of α-synuclein amplifies the binding with glyceraldehyde-3-phosphate dehydrogenase. Semenyuk P; Barinova K; Muronetz V Int J Biol Macromol; 2019 Apr; 127():278-285. PubMed ID: 30658140 [TBL] [Abstract][Full Text] [Related]
34. Natural products as anti-glycation agents: possible therapeutic potential for diabetic complications. Elosta A; Ghous T; Ahmed N Curr Diabetes Rev; 2012 Mar; 8(2):92-108. PubMed ID: 22268395 [TBL] [Abstract][Full Text] [Related]
35. Glycotoxines, carbonyl stress and relevance to diabetes and its complications. Turk Z Physiol Res; 2010; 59(2):147-156. PubMed ID: 19537931 [TBL] [Abstract][Full Text] [Related]
36. Antiglycation therapy: Discovery of promising antiglycation agents for the management of diabetic complications. Abbas G; Al-Harrasi AS; Hussain H; Hussain J; Rashid R; Choudhary MI Pharm Biol; 2016; 54(2):198-206. PubMed ID: 25853955 [TBL] [Abstract][Full Text] [Related]
37. Nitration and Glycation Diminish the α-Synuclein Role in the Formation and Scavenging of Cu Martínez-Orozco H; Mariño L; Uceda AB; Ortega-Castro J; Vilanova B; Frau J; Adrover M ACS Chem Neurosci; 2019 Jun; 10(6):2919-2930. PubMed ID: 30973706 [TBL] [Abstract][Full Text] [Related]
38. Skin beautification with oral non-hydrolized versions of carnosine and carcinine: Effective therapeutic management and cosmetic skincare solutions against oxidative glycation and free-radical production as a causal mechanism of diabetic complications and skin aging. Babizhayev MA; Deyev AI; Savel'yeva EL; Lankin VZ; Yegorov YE J Dermatolog Treat; 2012 Oct; 23(5):345-84. PubMed ID: 21756141 [TBL] [Abstract][Full Text] [Related]
39. Maillard Proteomics: Opening New Pages. Soboleva A; Schmidt R; Vikhnina M; Grishina T; Frolov A Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29231845 [TBL] [Abstract][Full Text] [Related]
40. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Olanow CW; Brundin P Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]